Nasdaq · CIK 0001785279
MGX Metagenomi, Inc.
Insider trading from SEC Form 4. Last filing 31 d ago. Close $1.00 on Oct 9, 2026, +2% from the 52-week low and -70% from the high.
Last 90 days
Net insider value
+$18k
more bought than sold
Buys
1
$23k by 1 insider
Sells
3
$5,107 by 3 insiders
Insiders on file
9
with a Form 4 at this company
Price and insider trades, last year
MGXOct 9, 2026 · close 1.00
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Metagenomi, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | Laurence Reid director buy | $23k 20,000 shares | - | - | |
| 30Weak | Jian Irish See Remarks sell | $2,479 2,140 shares | -1% | - | |
| 37Weak | Pamela Wapnick Chief Financial Officer sell | $2,214 1,911 shares | -1% | - | |
| 30Weak | Matthew Wein See Remarks sell | $415 358 shares | -0% | - | |
| 30Weak | Jian Irish See Remarks sell | $11k 6,390 shares | -2% | +37% from low-59% from high | |
| 40Moderate | Brian C. Thomas Chief Executive Officer sell | $19k 10,785 shares | -0% | +37% from low-59% from high | |
| 37Weak | Pamela Wapnick Chief Financial Officer sell | $2,758 1,576 shares | -2% | +37% from low-59% from high | |
| 30Weak | Sarah B. Noonberg Chief Medical Officer sell | $9,168 5,239 shares | -5% | +37% from low-59% from high | |
| 30Weak | Matthew Wein See Remarks sell | $348 199 shares | -1% | +37% from low-59% from high | |
| 22Weak | Pamela Wapnick Chief Financial Officer sell | $2,900 1,559 shares | -2% | - |
Transactions
The last 27 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | Laurence Reid director | POpen-market purchase Common Stock | +19,883 | $1.17 | $23k | 19,883 | 31 d ago |
| Sep 9, 2026 | Laurence Reid director | POpen-market purchase Common Stock | +117 | $1.18 | $138 | 20,000 | 31 d ago |
| Sep 8, 2026 | Jian Irish See Remarks | SOpen-market sale Common Stock | -2,140 | $1.16 | $2,479 | 375,393 | 32 d ago |
| Sep 8, 2026 | Pamela Wapnick Chief Financial Officer | SOpen-market sale Common Stock | -1,911 | $1.16 | $2,214 | 206,580 | 32 d ago |
| Sep 8, 2026 | Matthew Wein See Remarks | SOpen-market sale Common Stock | -358 | $1.16 | $415 | 126,133 | 32 d ago |
| Jun 10, 2025 | Eric Bjerkholt director | AGrant or award Stock Option (Right to Buy)derivative | +8,572 | $0.00 | $0 | 8,572 | Jun 12, 2025 |
| Jun 10, 2025 | Willard H Dere director | AGrant or award Stock Option (Right to Buy)derivative | +21,000 | $0.00 | $0 | 21,000 | Jun 12, 2025 |
| Jun 10, 2025 | Juergen Eckhardt director | AGrant or award Stock Option (Right to Buy)derivative | +21,000 | $0.00 | $0 | 21,000 | Jun 12, 2025 |
| Jun 6, 2025 | Jian Irish See Remarks | SOpen-market sale Common Stock | -6,390 | $1.75 | $11k | 315,543 | Jun 9, 2025 |
| Jun 6, 2025 | Matthew Wein See Remarks | SOpen-market sale Common Stock | -199 | $1.75 | $348 | 16,693 | Jun 9, 2025 |
| Jun 6, 2025 | Sarah B. Noonberg Chief Medical Officer | SOpen-market sale Common Stock | -5,239 | $1.75 | $9,168 | 109,135 | Jun 9, 2025 |
| Jun 6, 2025 | Pamela Wapnick Chief Financial Officer | SOpen-market sale Common Stock | -1,576 | $1.75 | $2,758 | 72,108 | Jun 9, 2025 |
| Jun 6, 2025 | Brian C. Thomas Chief Executive Officer | SOpen-market sale Common Stock | -10,785 | $1.75 | $19k | 2,517,491 | Jun 9, 2025 |
| Apr 1, 2025 | Jian Irish See Remarks | AGrant or award Common Stock | +23,000 | $0.00 | $0 | 321,933 | Apr 3, 2025 |
| Apr 1, 2025 | Pamela Wapnick Chief Financial Officer | AGrant or award Common Stock | +14,000 | $0.00 | $0 | 73,684 | Apr 3, 2025 |
| Apr 1, 2025 | Brian C. Thomas Chief Executive Officer | AGrant or award Common Stock | +32,000 | $0.00 | $0 | 2,528,276 | Apr 3, 2025 |
| Apr 1, 2025 | Matthew Wein See Remarks | AGrant or award Common Stock | +3,650 | $0.00 | $0 | 13,117 | Apr 3, 2025 |
| Apr 1, 2025 | Sarah B. Noonberg Chief Medical Officer | AGrant or award Common Stock | +14,000 | $0.00 | $0 | 114,374 | Apr 3, 2025 |
| Apr 1, 2025 | Sarah B. Noonberg Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +84,000 | $0.00 | $0 | 84,000 | Apr 3, 2025 |
| Apr 1, 2025 | Matthew Wein See Remarks | AGrant or award Common Stock | +3,775 | $0.00 | $0 | 16,892 | Apr 3, 2025 |
| Apr 1, 2025 | Brian C. Thomas Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +196,000 | $0.00 | $0 | 196,000 | Apr 3, 2025 |
| Apr 1, 2025 | Pamela Wapnick Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +84,000 | $0.00 | $0 | 84,000 | Apr 3, 2025 |
| Apr 1, 2025 | Matthew Wein See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +21,875 | $0.00 | $0 | 21,875 | Apr 3, 2025 |
| Apr 1, 2025 | Matthew Wein See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +22,725 | $0.00 | $0 | 22,725 | Apr 3, 2025 |
| Apr 1, 2025 | Jian Irish See Remarks | AGrant or award Stock Option (Right to Buy)derivative | +140,000 | $0.00 | $0 | 140,000 | Apr 3, 2025 |
| Feb 3, 2025 | Eric Bjerkholt director | AGrant or award Stock Option (Right to Buy)derivative | +42,000 | $0.00 | $0 | 42,000 | Feb 5, 2025 |
| Dec 5, 2024 | Pamela Wapnick Chief Financial Officer | SOpen-market sale Common Stock | -1,559 | $1.86 | $2,900 | 61,492 | Dec 6, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Eric Bjerkholtcfo, officer, director
- Willard H Deredirector
- Juergen Eckhardtdirector
- Jian IrishSee Remarks
- Sarah B. NoonbergChief Medical Officer
- Laurence Reiddirector
- Brian C. ThomasChief Executive Officer
- Pamela WapnickChief Financial Officer
- Matthew WeinSee Remarks
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.